Context Therapeutics (Context Therapeutics) Price-to-Tangible-Book : 2.26 (As of May. 14, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Context Therapeutics Price-to-Tangible-Book?

As of today (2024-05-14), Context Therapeutics's share price is $1.68. Context Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.74. Hence, Context Therapeutics's Price to Tangible Book Ratio of today is 2.26.

The historical rank and industry rank for Context Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

CNTX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.3 Med: 0.88 Max: 2.54
Current: 2.27

During the past 5 years, Context Therapeutics's highest Price to Tangible Book Ratio was 2.54. The lowest was 0.30. And the median was 0.88.

CNTX's Price-to-Tangible-Book is ranked better than
53.61% of 1220 companies
in the Biotechnology industry
Industry Median: 2.71 vs CNTX: 2.27

A closely related ratio is called PB Ratio. As of today, Context Therapeutics's share price is $1.68. Context Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.74. Hence, Context Therapeutics's P/B Ratio of today is 2.26.

Context Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Context Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Context Therapeutics Price-to-Tangible-Book Chart

Context Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

0.88

0.30

1.52

Context Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial												0.30	0.31	1.06	1.31	1.52

Competitive Comparison of Context Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Context Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Context Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Context Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Context Therapeutics's Price-to-Tangible-Book falls into.

Context Therapeutics Price-to-Tangible-Book Calculation

Context Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	1.68	/	0.744
	=	2.26

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Context Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Context Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Context Therapeutics (Context Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Context Therapeutics Inc (NAS:CNTX) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

6K9:Germany

Address

2001 Market Street, Suite 3915, Unit No. 15, Philadelphia, PA, USA, 19103

Website

https://www.contexttherapeutics.com

Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.

Executives

Martin A. Lehr	director, officer: Chief Executive Officer	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Jennifer Lynn Minai-azary	officer: Chief Financial Officer	110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Alex C. Levit	officer: Chief Legal Officer, Corp. Sec	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Tarek Sahmoud	officer: Chief Medical Officer	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Richard J Berman	director	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Jennifer Evans Stacey	director	AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401
Linda West	director	C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD., #110, MALVERN PA 19355
Evan G. Dick	officer: SVP of R&D	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
William F. Rencher	officer: Head of CMC and Regulatory	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Philip W. Kantoff	director	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104